PTX 0.00% 3.9¢ prescient therapeutics limited

VHL - Transgene TG4011 & TG4010, page-5

  1. 1,656 Posts.
    lightbulb Created with Sketch. 198
    Cornhulio, following link on current proceedings.
    December 7, 2016 - UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) / The trial will be supported by Transgene and Bristol-Myers Squibb http://www.transgene.fr/wp-content/...7-Collaboration_UC_Davis_Transgene-BMS_EN.pdf
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.